Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as children.

A total of 128/200 treatment-naïve prepubertal children with GHD consented to baseline blood transcriptome profiling.

How the Study Was Run

The design is described as randomized, open-label and parallel-group.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.

Groups ran in parallel: each of the participants stayed in one arm throughout.

REAL4 is a randomized, multinational, open-label, active-controlled parallel group phase 3 trial, comprising a 52-week main phase and an ongoing 3-year safety extension (NCT03811535).

Differential RNA-seq analysis and machine learning were used to predict therapy response.

What Was Measured

Topics PubMed links to this paper include Body Height, Dwarfism, Pituitary, Growth Hormone, Histidine, Human Growth Hormone, Insulin-Like Growth Factor I and Mannitol.

The authors tagged it with the keywords and RNA sequencing, growth hormone deficiency, long-acting growth hormone, predictive markers, pretreatment blood transcriptome and somapacitan.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.